renegade.bio is a technology company.
renegade.bio has raised $330K across 1 funding round.
renegade.bio has raised $330K in total across 1 funding round.
renegade.bio has raised $330K in total across 1 funding round.
renegade.bio's investors include At One Ventures, B Capital Group, Big Idea Ventures, Bluestein Ventures, Founders Fund, Mayfield, Pareto Holdings, SOSV, Vitalize Venture Group, Mark Cuban, Sahin Boydas, Scot Wingo.
# Renegade.bio: High-Level Overview
Renegade.bio is a diagnostics company, not a general technology company. It is a purpose-driven, queer-led public benefit corporation that develops and distributes innovative diagnostic testing solutions to underserved populations[2]. The company addresses a critical gap in healthcare accessibility by creating pathways for cutting-edge diagnostics to reach communities that have historically lacked equitable access to testing and disease detection.
The company operates through two complementary divisions: Renegade Science, which develops proprietary diagnostic assays and leverages capabilities in biomarker discovery, PCR, NGS, and LCMS[1], and Renegade Reach, which creates distribution channels through partnerships with local clinics, hospitals, and community organizations[1]. Rather than building software or infrastructure platforms, Renegade.bio solves the problem of diagnostic inaccessibility by combining scientific innovation with community-focused logistics. The company serves individuals, workplaces, schools, communities, and public health organizations[6], with particular focus on women, queer, and BIPOC communities[2].
# Origin Story
Renegade.bio was founded in 2020 and is headquartered in Berkeley, California[6]. The company emerged directly from the COVID-19 pandemic, when co-founder and CEO Craig Rouskey and his team mobilized to provide rapid, accessible coronavirus testing to healthcare workers, first responders, and underserved communities in New York and the San Francisco Bay Area[2][4]. This crisis response revealed a systemic problem: diagnostic capacity and access were concentrated in ways that left vulnerable populations behind. Rather than treating this as a temporary pandemic response, the founders built a permanent organization around the principle that diagnostics should be a public health tool, not a luxury service.
The company's early traction included organizing COVID-19 testing programs for major organizations including the United Nations, the NBA, San Francisco Giants, schools, and skilled nursing facilities[2]. This demonstrated both the demand for accessible testing and the operational capability to scale rapidly.
# Core Differentiators
# Role in the Broader Healthcare Landscape
Renegade.bio operates at the intersection of two critical trends: the recognition that health equity requires systemic change, not just individual interventions, and the growing understanding that early disease detection through accessible diagnostics reduces overall healthcare costs and improves outcomes[2]. The company's existence reflects a market failure—diagnostic innovation exists, but distribution mechanisms systematically exclude low-income and historically marginalized communities.
By demonstrating that diagnostics can be developed, validated, and deployed through community partnerships rather than traditional pharmaceutical distribution, Renegade.bio influences how the broader biotech ecosystem thinks about access. Their model suggests that solving healthcare inequity requires not just better science, but better logistics and community trust.
# Quick Take & Future Outlook
Renegade.bio is positioned at an inflection point where public health crises (pandemic, monkeypox, emerging pathogens) create both urgency and funding for diagnostic accessibility. The company's expansion from COVID-19 to monkeypox to partnerships addressing pre-eclampsia[2] suggests a trajectory toward becoming a platform for rapid diagnostic deployment across multiple disease areas affecting underserved populations.
The key question for their evolution is whether they can scale this model beyond crisis response into sustained, routine diagnostic access for disease prevention—a shift from emergency triage to preventive medicine infrastructure. If successful, Renegade.bio could redefine how public health systems approach diagnostic capacity, moving from centralized, expensive testing to distributed, community-embedded networks. Their success or failure will signal whether mission-driven, equity-focused biotech can compete with traditional diagnostics companies in speed, cost, and scale.
renegade.bio has raised $330K across 1 funding round. Most recently, it raised $330K Seed in April 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2020 | $330K Seed | At One Ventures, B Capital Group, Big Idea Ventures, Bluestein Ventures, Founders Fund, Mayfield, Pareto Holdings, SOSV, Vitalize Venture Group, Mark Cuban, Sahin Boydas, Scot Wingo |